Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
donor-derived NK cell infusion · 1 trial · 1 indication
assessment of adverse events
| Arm | Type | Description |
|---|---|---|
| PB103 (donor-derived NK cells) infusion | EXPERIMENTAL | Cohort 1: 0.5×10\^9，Cohort 2:1×10\^9 or Cohort 3: 1.5×10\^9 cells |
| Name | Type | Description |
|---|---|---|
| donor-derived NK cell infusion | BIOLOGICAL | PB103 administrations will be separated by 4-week interval |
Inclusion Criteria: Recipient: 1. Recipients (Subjects) are between 20-70 years of age. 2. Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥ 4/8 match at HLA-A, -B, -C and -DRb1 3. Signed informed consent. 4. Subjects with histologically or cytologically confirmed non -sm...
Top 20 of 84 competitors
Donor-derived NK cell infusion is an investigational cell therapy being studied for the treatment of Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 1 clinical development, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
Donor-derived NK cell infusion is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial to evaluate this investigational therapy in patients with Non-small Cell Lung Cancer.
Donor-derived NK cell infusion is currently in Phase 1 clinical development. This is an early-stage trial designed to assess the safety, tolerability, and preliminary efficacy of the investigational therapy in patients with Non-small Cell Lung Cancer. The drug is not yet approved for commercial use.
Donor-derived NK cell infusion is being evaluated in a single Phase 1 clinical trial with the identifier NCT04616209. This open-label, uncontrolled study is recruiting approximately 24 participants with Non-small Cell Lung Cancer in Taiwan. The trial is actively enrolling patients aged 20 years and older.
Yes, donor-derived NK cell infusion is also known as PB103. The clinical trial NCT04616209, titled 'Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients,' is evaluating this investigational cell therapy. The drug is being studied as a potential treatment for Non-small Cell Lung Cancer.